A study of peginterferon alfa-2a in combination with ribavirin in chronic hepatitis C(CHC) patients with compensated liver cirrhosis(LC).
Phase 2
- Conditions
- CHC with compensated LC
- Registration Number
- JPRN-jRCT2080220215
- Lead Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Male and Female patients aged 20 to 75 years-old, diagnosed CHC with compensated LC, elevated ALT and detectable HCV RNA.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy and safety
- Secondary Outcome Measures
Name Time Method